{"doi":"10.1002/art.41931","title":"<scp>Anti‐Cortactin</scp> Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis","abstract":"OBJECTIVE: To define the prevalence and clinical phenotype of anti-cortactin autoantibodies in adult and juvenile myositis. METHODS: In this longitudinal cohort study, anti-cortactin autoantibody titers were assessed by enzyme-linked immunosorbent assay in 670 adult myositis patients and 343 juvenile myositis patients as well as in 202 adult healthy controls and 90 juvenile healthy controls. The prevalence of anti-cortactin autoantibodies was compared among groups. Clinical features of patients with and those without anti-cortactin autoantibodies were also compared. RESULTS: Anti-cortactin autoantibodies were more common in adult dermatomyositis (DM) patients (15%; P = 0.005), particularly those with coexisting anti-Mi-2 autoantibodies (24%; P = 0.03) or anti-NXP-2 autoantibodies (23%; P = 0.04). In adult myositis, anti-cortactin was associated with DM skin involvement (62% of patients with anti-cortactin versus 38% of patients without anti-cortactin; P = 0.03), dysphagia (36% versus 17%; P = 0.02) and coexisting anti-Ro 52 autoantibodies (47% versus 26%; P = 0.001) or anti-NT5c1a autoantibodies (59% versus 33%; P = 0.001). Moreover, the titers of anti-cortactin antibodies were higher in patients with interstitial lung disease (0.15 versus 0.12 arbitrary units; P = 0.03). The prevalence of anti-cortactin autoantibodies was not different in juvenile myositis patients (2%) or in any juvenile myositis subgroup compared to juvenile healthy controls (4%). Nonetheless, juvenile myositis patients with these autoantibodies had a higher prevalence of \"mechanic's hands\" (25% versus 7%; P = 0.03), a higher number of hospitalizations (2.9 versus 1.3; P = 0.04), and lower peak creatine kinase values (368 versus 818 IU/liter; P = 0.02) than those without anti-cortactin. CONCLUSION: The prevalence of anti-cortactin autoantibodies is increased in adult DM patients with coexisting anti-Mi-2 or anti-NXP-2 autoantibodies. In adults, anti-cortactin autoantibodies are associated with dysphagia and interstitial lung disease.","journal":"Arthritis & Rheumatology","year":2021,"id":200312,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.96,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2021-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":260868,"name":"Katherine Pak","orcid":null,"position":1,"is_corresponding":false},{"id":732849,"name":"Albert Gil‐Vila","orcid":"0000-0003-2786-2009","position":2,"is_corresponding":false},{"id":777528,"name":"Andrés Baucells","orcid":"0000-0002-4567-8486","position":3,"is_corresponding":false},{"id":711303,"name":"Benjamin Plotz","orcid":"0000-0002-7022-7177","position":4,"is_corresponding":false},{"id":257663,"name":"María Casal-Domínguez","orcid":"0000-0002-3905-3922","position":5,"is_corresponding":false},{"id":260867,"name":"Assia Derfoul","orcid":null,"position":6,"is_corresponding":false},{"id":777968,"name":"Maria Angeles Martinez‐Carretero","orcid":null,"position":7,"is_corresponding":false},{"id":250483,"name":"Albert Selva-O’Callaghan","orcid":"0000-0003-2823-9761","position":8,"is_corresponding":false},{"id":337963,"name":"Sara Sabbagh","orcid":"0000-0003-3176-9958","position":9,"is_corresponding":false},{"id":257451,"name":"Livia Casciola‐Rosen","orcid":"0000-0002-4172-1539","position":10,"is_corresponding":false},{"id":257453,"name":"Jemima Albayda","orcid":"0000-0002-8030-9504","position":11,"is_corresponding":false},{"id":257450,"name":"Julie J. Paik","orcid":"0000-0001-8436-1601","position":12,"is_corresponding":false},{"id":257454,"name":"Eleni Tiniakou","orcid":"0000-0003-4749-870X","position":13,"is_corresponding":false},{"id":264742,"name":"Sonye K. Danoff","orcid":"0000-0001-9172-8977","position":14,"is_corresponding":false},{"id":257667,"name":"Thomas E. Lloyd","orcid":"0000-0003-4756-3700","position":15,"is_corresponding":false},{"id":247406,"name":"Frederick W. Miller","orcid":"0000-0003-2831-9593","position":16,"is_corresponding":false},{"id":264511,"name":"Lisa G. Rider","orcid":"0000-0002-6912-2458","position":17,"is_corresponding":false},{"id":257459,"name":"Lisa Christopher‐Stine","orcid":"0000-0002-7150-7306","position":18,"is_corresponding":false},{"id":257669,"name":"Andrew L. Mammen","orcid":"0000-0003-3732-3252","position":19,"is_corresponding":false},{"id":777969,"name":"the Childhood Myositis Heterogeneity Collaborative Study Group","orcid":null,"position":20,"is_corresponding":false},{"id":250478,"name":"Iago Pinal‐Fernandez","orcid":"0000-0001-6338-9218","position":0,"is_corresponding":true}],"reference_count":21,"raw_metadata":null,"created_at":"2026-07-18T23:50:44.479665Z","pmid":"34313394","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}